Japan Approves Sanofi's Sarclisa SC for Multiple Myeloma, Expanding Global Reach
Summary
Japan has approved Sanofi's Sarclisa subcutaneous (SC) formulation for multiple myeloma, following its recent EU approval earlier this month. This expands market access for Sarclisa in a major market, offering a more convenient treatment option for patients compared to intravenous administration. The SC formulation, which could eventually be administered via an on-body injector, aims to improve patient experience and potentially increase market share in Japan's growing multiple myeloma patient population. A regulatory submission for the on-body injector is under review in Japan, and a similar application for Sarclisa SC is pending in the US.
At the time of this announcement, SNY was trading at $42.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $101.3B. The 52-week trading range was $41.86 to $52.68. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.